share_log

Purple Biotech Analyst Ratings

Purple Biotech Analyst Ratings

紫色生物技術分析師評級
Benzinga ·  2023/07/21 05:12
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/21/2023 566.67% JonesTrading → $8 Initiates Coverage On → Buy
05/17/2023 483.33% HC Wainwright & Co. → $7 Reiterates Buy → Buy
05/17/2023 816.67% Chardan Capital → $11 Reiterates Buy → Buy
02/09/2023 483.33% HC Wainwright & Co. → $7 Reiterates → Buy
02/09/2023 816.67% Chardan Capital → $11 Reiterates → Buy
10/17/2022 483.33% HC Wainwright & Co. → $7 Initiates Coverage On → Buy
09/08/2022 816.67% Chardan Capital → $11 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
07/21/2023 566.67% JonesTrading → 8 美元 啓動覆蓋開啓 → 購買
05/17/2023 483.33% HC Wainwright & Co. → 7 美元 重申 購買 → 購買
05/17/2023 816.67% 查丹資本 → 11 美元 重申 購買 → 購買
02/09/2023 483.33% HC Wainwright & Co. → 7 美元 重申 → 購買
02/09/2023 816.67% 查丹資本 → 11 美元 重申 → 購買
2022 年 10 月 17 日 483.33% HC Wainwright & Co. → 7 美元 啓動覆蓋開啓 → 購買
09/08/2022 816.67% 查丹資本 → 11 美元 啓動覆蓋開啓 → 購買

What is the target price for Purple Biotech (PPBT)?

紫色生物科技(PPBT)的目標價格是多少?

The latest price target for Purple Biotech (NASDAQ: PPBT) was reported by JonesTrading on July 21, 2023. The analyst firm set a price target for $8.00 expecting PPBT to rise to within 12 months (a possible 566.67% upside). 7 analyst firms have reported ratings in the last year.

JoneStrading於2023年7月21日公佈了紫色生物科技(納斯達克股票代碼:PPBT)的最新目標股價。這家分析公司將目標股價定爲8.00美元,預計PPBT將在12個月內升至12個月內(可能上漲566.67%)。去年有7家分析公司公佈了評級。

What is the most recent analyst rating for Purple Biotech (PPBT)?

紫色生物科技(PPBT)的最新分析師評級是多少?

The latest analyst rating for Purple Biotech (NASDAQ: PPBT) was provided by JonesTrading, and Purple Biotech initiated their buy rating.

紫色生物科技(納斯達克股票代碼:PPBT)的最新分析師評級由JoneStrading提供,Purple Biotech啓動了買入評級。

When is the next analyst rating going to be posted or updated for Purple Biotech (PPBT)?

Purple Biotech(PPBT)的下一個分析師評級何時公佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Purple Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Purple Biotech was filed on July 21, 2023 so you should expect the next rating to be made available sometime around July 21, 2024.

分析師在進行了廣泛的研究(包括瀏覽公開財務報表、與Purple Biotech的高管和客戶交談以及聽取財報電話會議)後得出了股票評級。大多數分析師每三個月進行一次評級,因此每家公司每年應該獲得4個評級。Purple Biotech的最後一次評級是在2023年7月21日提交的,因此您應該預計下一個評級將在2024年7月21日左右公佈。

Is the Analyst Rating Purple Biotech (PPBT) correct?

分析師對 Purple Biotech (PPBT) 的評級是否正確?

While ratings are subjective and will change, the latest Purple Biotech (PPBT) rating was a initiated with a price target of $0.00 to $8.00. The current price Purple Biotech (PPBT) is trading at is $1.20, which is within the analyst's predicted range.

雖然評級是主觀的,會發生變化,但最新的Purple Biotech(PPBT)評級是最初的,目標股價爲0.00美元至8.00美元。Purple Biotech(PPBT)目前的交易價格爲1.20美元,在分析師的預測區間內。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論